Result of General Meeting

24 November 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, announces that the resolution put to the General Meeting held earlier today was duly passed.  The Company will now proceed to cancel the listing of its Ordinary Shares on the Official List and to remove such Ordinary Shares from trading on the Main Market of the London Stock Exchange and apply for its Ordinary Shares to be admitted to trading on AIM.

Voting figures will be displayed shortly on the Company's investor website at http://investor.puricore.com. The resolution will be available shortly for inspection at the National Storage Mechanism at www.hemscott.com/nsm.do.

Next steps

It is expected that the last day of dealings in the Ordinary Shares on the Main Market will be 22 December 2014. Cancellation of the listing of Ordinary Shares on the Official List is expected to become effective at 8.00 a.m. on 23 December 2014. Admission is expected to take place, and dealings in Ordinary Shares are expected to commence on AIM, at 8.00 a.m. on 23 December 2014.

In accordance with the AIM admission procedure for a company already quoted on a 'designated market', the Company will submit to AIM a Schedule 1 pre-admission announcement. It is expected that the Schedule 1 will be published tomorrow on the Company's website, together with an Appendix document containing all information that is required to be included in an AIM Admission Document which is not currently public.

Except as otherwise defined herein, capitalised terms have the same meanings as set out in the Circular dated 7 November 2014.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in a well-established core business and emerging sectors of two broad markets: Food & Agriculture and Health Sciences. In the Food & Agriculture market, PuriCore's portfolio is used by thousands of US supermarket retailers, including three of the top-five, to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In the Health Sciences market, PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. PuriCore is headquartered in Malvern, Pennsylvania. To receive additional information on PuriCore, visit www.puricore.com.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.